Next 10 |
2024-05-16 18:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensili...
2024-05-13 07:58:54 ET Merck ( NYSE: MRK ) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial .... Read the full article on Seeking Alpha For further details see: Merck discontinues testing of experimental skin...
2024-05-07 17:45:24 ET Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q1 2024 Earnings Call May 07, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q1 2024 Earnings Call Transcript
2024-05-07 13:45:21 ET Agenus Inc. (AGEN) Q1 2024 Earnings Conference Call May 7, 2024 08:30 ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman & Chief Executive Officer Steven O’Day - Chief Medical Officer Robin ...
2024-05-07 10:01:47 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...
2024-05-07 08:02:01 ET More on Ligand Pharmaceuticals Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio Ovid Therapeutics gains on bullish view at Wedbush Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals Read the f...
2024-05-07 07:46:10 ET More on Agenus Agenus: A Would-Be Rockstar Held Back By Middling Financials Agenus reports updated Phase 1 data on colorectal cancer therapy Read the full article on Seeking Alpha For further details see: Agenus GAAP EPS of -$3.04 b...
$100M royalty financing agreement with Ligand announced, bringing in capital via non-equity means to support critical botensilimab/balstilimab (BOT/BAL) development and launch readiness activities Company has reestablished its market compliance with Nasdaq Listing Notable clinical...
Capital infusion will support botensilimab and balstilimab (BOT/BAL) clinical development, confirmatory Phase 3 trial, and launch readiness activities Ligand entitled to royalties and milestone payments on six Agenus-partnered programs as well as royalties on future global net sales gener...
News, Short Squeeze, Breakout and More Instantly...
2024-05-16 18:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensili...
2024-05-07 17:45:24 ET Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q1 2024 Earnings Call May 07, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q1 2024 Earnings Call Transcript